Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30218086 | 1.00 | LPL (0.38) | LPLLIPGALDH1A1HSD17B10EGFR | |
| SCHEMBL24498805 | 0.76 | LPL (0.34) | LPLLIPGEGFR | |
| SCHEMBL30741244 | 0.76 | LPL (0.34) | LPLLIPGEGFR | |
| SCHEMBL28473905 | 0.75 | LPL (0.35) | LPLLIPG | |
| SCHEMBL658450 | 0.75 | LPL (0.38) | LPLLIPGALDH1A1HSD17B10EGFR | |
| SCHEMBL25244339 | 0.74 | LPL (0.32) | LPLLIPG | |
| SCHEMBL21805337 | 0.74 | ALDH1A1 (0.35) | LPLLIPGALDH1A1HSD17B10 | |
| SCHEMBL32691468 | 0.73 | LPL (0.34) | LPLLIPGEGFR | |
| SCHEMBL25176467 | 0.73 | LPL (0.31) | LPLLIPG | |
| SCHEMBL31082986 | 0.73 | LPL (0.31) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590105-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-12441742-B2 | Naphthyridine compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4396187-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| EP-2411398-B1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8785651-B2 | Method for manufacturing a boronic acid ester compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20120123122-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | GENENTECH, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2411398-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010110782-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441742-B2 | Naphthyridine compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | LPL 3919/4885LIPG 2426/4885ALDH1A1 2186/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | LPL 2/4885LIPG 17/4885ALDH1A1 587/4885 |
| US-12590105-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | LPL 4573/4885LIPG 4420/4885ALDH1A1 2890/4885 |
| US-20150038488-A1 | SYK INHIBITORS | SYK, BTK, LYN | LPL 3078/4885LIPG 1649/4885ALDH1A1 4200/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | LPL 2221/4885LIPG 2618/4885ALDH1A1 128/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | LPL 2221/4885LIPG 2618/4885ALDH1A1 128/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | LPL 2221/4885LIPG 2618/4885ALDH1A1 128/4885 |
| US-20120123122-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | NISCH, BRSK1, BLK | LPL 1463/4885LIPG 3166/4885ALDH1A1 4174/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | LPL 2221/4885LIPG 2618/4885ALDH1A1 128/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | LPL 1131/4885LIPG 1319/4885ALDH1A1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.